Prednisone
(Synonyms: 强的松; Dehydrocortisone) 目录号 : GC16450
A synthetic glucocorticoid
Cas No.:53-03-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Peripheral blood lymphocytes (PBL) or peripheral CD4+ and CD8+ T cell subsets |
|
Preparation method |
The solubility of this compound in DMSO is > 15.4 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
10-3 ~ 10-12 M; 72, 96 and 120 hrs |
|
Applications |
Prednisone arrested PBL in the G1 phase of cell cycle, and inhibited IL-2 receptor (IL-2R) expression as well as IL-2 secretion. In phytohaemaglutinin (PHA)-activated human PBL, Prednisone significantly increased apoptosis. Moreover, Prednisone exhibited stronger apoptotic effect on CD8+ T lymphocytes than on CD4+ T lymphocytes. All these effects were shown in dose- and time-dependent manners. |
| Animal experiment [2]: | |
|
Animal models |
Male Wistar rats |
|
Dosage form |
5 mg/kg/d; p.o.; for 90 days |
|
Applications |
In Wistar rats, Prednisone significantly delayed learning and memory retention by 20%. Compared with the control group, the neuronal degeneration index in the Prednisone treatment group was 2 times higher in the prefrontal cortex, and about 10 times higher in the CA1 hippocampus. In addition, Prednisone substantially increased the number and cytoplasmic transformation of astrocytes, as well as isolectin-B4-labeled microglia cells in the prefrontal cortex. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, Filaci G, Fecarotta E, Vidali G, Indiveri F. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol. 1996 Mar;103(3):482-90. [2]. Ramos-Remus C, González-Castaeda RE, González-Perez O, Luquin S, García-Estrada J. Prednisone induces cognitive dysfunction, neuronal degeneration, and reactive gliosis in rats. J Investig Med. 2002 Nov;50(6):458-64. |
|
Prednisone (Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.Target: OthersPrednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases (such as moderate allergic reactions) and (at higher doses) some types of cancer, but has significant adverse effects. Because it suppresses the immune system, it leaves patients more susceptible to infections.Prednisone can also be used in the treatment of decompensated heart failure to potentiate renal responsiveness to diuretics, especially in heart failure patients with refractory diuretic resistance with large dose of loop diuretics. The mechanism is prednisone, as a glucocorticoid, can improve renal responsiveness to atrial natriuretic peptide by increasing the density of natriuretic peptide receptor type A in the renal inner medullary collecting duct, inducing a potent diuresis.
References:
[1]. RIEMER AD. Application of the newer corticosteroids to augment diuresis in congestive heart failure. Am J Cardiol. 1958 Apr;1(4):488-96.
[2]. Zhang H, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. 2008 Sep;49(5):587-95.
| Cas No. | 53-03-2 | SDF | |
| 别名 | 强的松; Dehydrocortisone | ||
| 化学名 | (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione | ||
| Canonical SMILES | CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C | ||
| 分子式 | C21H26O5 | 分子量 | 358.43 |
| 溶解度 | ≥ 15.35mg/mL in DMSO | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7899 mL | 13.9497 mL | 27.8995 mL |
| 5 mM | 0.558 mL | 2.7899 mL | 5.5799 mL |
| 10 mM | 0.279 mL | 1.395 mL | 2.7899 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。